Our neurodevelopmental preclinical research focuses on developing new targeted drug treatments in
developmental disabilities. We utilize mouse models of Fragile X Syndrome, Angelman Syndrome, and autism spectrum disorders to identify novel targets. The lab tests the effectiveness of new compounds and repurposed drugs for the treatment of behavior, molecular, and cellular abnormalities associated with these disorders.
We are also developing novel biomarkers of disease pathophysiology and treatment response that will hopefully lead to more personalized treatment approaches and successful outcomes for children and adults with developmental disabilities.
To learn more about this research, visit the Gross Lab.